Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lanreotide versus placebo for carcinoid syndrome symptom control
2010-019066-92Phase 4Completed
- Sponsor
- Ipsen
- Start
- Jun 2010
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in Carcinoid Syndrome (CS) comparing Somatuline Depot with Placebo (2 arms). Primary endpoint: Use of subcutaneous octreotide rescue medication. Started Jun 2010; status: completed.
02
Drugs
lanreotide
03
Conditions
Carcinoid Syndrome (CS)
Beyond the preview
Go deeper on 2010-019066-92.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019066-92.